Autophagy is a catabolic membrane-trafficking process that occurs in all eukaryotic cells and leads to the hydrolytic degradation of cytosolic material in the vacuolar or lysosomal lumen. Mitophagy, a selective form of autophagy targeting mitochondria, is poorly understood at present. Several recent reports suggest that mitophagy is a selective process that targets damaged mitochondria, whereas other studies imply a role for mitophagy in cell death processes. In a screen for protein phosphatase homologs that functionally interact with the autophagy-dedicated protein kinase Atg1p in yeast, we have identified Aup1p, encoded by Saccharomyces cerevisiae reading frame YCR079w. Aup1p is highly similar to a family of protein phosphatase homologs in animal cells that are predicted to localize to mitochondria based on sequence analysis. Interestingly, we found that Aup1p localizes to the mitochondrial intermembrane space and is required for efficient mitophagy in stationary phase cells. Viability studies demonstrate that Aup1p is required for efficient survival of cells in prolonged stationary phase cultures, implying a pro-survival role for mitophagy under our working conditions. Our data suggest that Aup1p may be part of a signal transduction mechanism that marks mitochondria for sequestration into autophagosomes.Mitochondria perform numerous essential physiological functions in all eukaryotic cells. Apart from their role in oxidative phosphorylation and fatty acid oxidation, they are also essential for biosynthesis of central building blocks such as amino acids and nucleotides. At the same time, mitochondria are a threat to cellular well-being. Mitochondria are a major source of reactive oxygen species in cells. In addition, disruption of mitochondrial compartmentalization results in leakage of cytochrome c and other cytotoxic factors, and mitochondria with defective chemiosmotic coupling can cause an energy drain on the cell. Accumulation of mitochondrial genetic variation and mitochondrial damage are widely considered to underlie many age-related metabolic diseases and late-onset genetic disorders (1, 2). It is commonly postulated that in normal cells defective mitochondria are broken down in the lysosomal compartment through autophagy, and inability to clear defective mitochondria is thought to underlie numerous pathological conditions (3, 4).Autophagy is a set of catabolic membrane trafficking mechanisms that allow import of cytosolic material into the vacuole/ lysosome. The best understood form of autophagy is macroautophagy, in which intracellular membranes of undetermined origin engulf cytosolic material to form a double or multi-bilayer membrane bound intermediate called the autophagosome (reviewed in Refs. 3 and 5-8). This intermediate then goes on to fuse with the vacuole/lysosome, releasing a single-bilayer bound vesicle called an autophagic body into the lumen of the lytic compartment where it is broken down, releasing the cytosol-derived material for further degradation to biosynthetic building blocks. Cl...

Gut microbiome diversity has been strongly associated with mood-relating behaviours, including major depressive disorder (MDD). This association stems from the recently characterised bi-directional communication system between the gut and the brain, mediated by neuroimmune, neuroendocrine and sensory neural pathways. While the link between gut microbiome and depression is well supported by research, a major question needing to be addressed is the causality in the connection between the two, which will support the understanding of the role that the gut microbiota play in depression. In this article, we address this question by examining a theoretical 'chronology', reviewing the evidence supporting two possible sequences of events. First, we discuss that alterations in the gut microbiota populations of specific species might contribute to depression, and secondly, that depressive states might induce modification of specific gut microbiota species and eventually contribute to more severe depression. The feasibility of both sequences is supported by pre-clinical trials. For instance, research in rodents has shown an onset of depressive behaviour following faecal transplantations from patients with MDD. On the other hand, mental induction of stress and depressive behaviour in rodents resulted in reduced gut microbiota richness and diversity. Synthesis of these chronology dynamics raises important research directions to further understand the role that gut microbiota play in mood-relating behaviours, which holds substantial potential clinical outcomes for persons who experience MDD or related depressive disorders.

No abstract

Here we outline the principles of the different approaches and their relative advantages. We demonstrate the unique contribution of flux analysis for phenotype elucidation using a thoroughly studied metabolic reaction as a case study, the microbial aerobic/anaerobic shift, highlighting the importance of flux analysis as a single layer of data as well as interlaced in multi-omics studies.

No abstract

para-Hydroxy benzoic acid (PHBA) is the key component for preparing parabens, a common preservatives in food, drugs, and personal care products, as well as high-performance bioplastics such as liquid crystal polymers. Pseudomonas putida KT2440 was engineered to produce PHBA from glucose via the shikimate pathway intermediate chorismate. To obtain the PHBA production strain, chorismate lyase UbiC from Escherichia coli and a feedback resistant 3-deoxy-d-arabino-heptulosonate-7-phosphate synthase encoded by gene aroGD146N were overexpressed individually and simultaneously. In addition, genes related to product degradation (pobA) or competing for the precursor chorismate (pheA and trpE) were deleted from the genome. To further improve PHBA production, the glucose metabolism repressor hexR was knocked out in order to increase erythrose 4-phosphate and NADPH supply. The best strain achieved a maximum titer of 1.73 g L−1 and a carbon yield of 18.1% (C-mol C-mol−1) in a non-optimized fed-batch fermentation. This is to date the highest PHBA concentration produced by P. putida using a chorismate lyase.

Objective: Serotonin reuptake inhibitors are the predominant treatment for major depressive disorder. In recent years, the diversity of the gut microbiota has emerged to play a significant role in the occurrence of major depressive disorder and other mood and anxiety disorders. Importantly, the role of the gut microbiota in the treatment of such disorders remains to be elucidated. Here, we provide a review of the literature regarding the effects of physiologically relevant concentrations of serotonin reuptake inhibitors on the gut microbiota and the implications this might have on their efficacy in the treatment of mood disorders. Methods: First, an estimation of gut serotonin reuptake inhibitor concentrations was computed based on pharmacokinetic and gastrointestinal transit properties of serotonin reuptake inhibitors. Literature regarding the in vivo and in vitro antimicrobial properties of serotonin reuptake inhibitors was gathered, and the estimated gut concentrations were examined in the context of these data. Computer-based investigation revealed putative mechanisms for the antimicrobial effects of serotonin reuptake inhibitors. Results: In vivo evidence using animal models shows an antimicrobial effect of serotonin reuptake inhibitors on the gut microbiota. Examination of the estimated physiological concentrations of serotonin reuptake inhibitors in the gastrointestinal tract collected from in vitro studies suggests that the microbial community of both the small intestine and the colon are exposed to serotonin reuptake inhibitors for at least 4 hours per day at concentrations that are likely to exert an antimicrobial effect. The potential mechanisms of the effect of serotonin reuptake inhibitors on the gut microbiota were postulated to include inhibition of efflux pumps and/or amino acid transporters. Conclusion: This review raises important issues regarding the role that gut microbiota play in the treatment of mood-related behaviours, which holds substantial potential clinical outcomes for patients suffering from major depressive disorder and other mood-related disorders.

Soil phytopathogenic fungi are principally associated with crop diseases; however, the effects of fungal infection may extend beyond the field to human and animal consumers putting their health at risk. Mycotoxigenic fungi can produce secondary metabolites known as mycotoxins, which are considered to be toxic when present in human food and animal feed. Mycotoxins are characterized as odourless and tasteless compounds, thus their identification in food is difficult. Furthermore, mycotoxins are heat resistant and tolerate a wide range of pH, making them hard to breakdown. In this review we follow the fates of mycotoxins from the ecology of their producers in the soil to pre‐harvest occurrence in host plants, postharvest in storage and their effect on human well‐being, focusing on aflatoxin as a case study. Aflatoxin production begins in the soil, the natural habitat of toxin‐producing fungi of the Aspergillus spp., and its production is influenced by agricultural practices, environmental conditions and fungal interaction with the plant. The fungi are further dispersed during storage, which leads to a vast increase in toxin concentration during the storage period. Aflatoxin may then be consumed by humans or animals in raw or processed foods and feeds, respectively. Animal consumption of the toxin might carry over to humans in animal food products, such as milk. Once consumed, various forms of aflatoxin are recognized as human carcinogens and exposure is mainly associated with the development of hepatocellular carcinoma. The presence of mycotoxins in foods also carries severe economic implications because of the loss of crops, the cost of analysis and enforcement of a regulatory system. This review provides a critical analysis of each of these stages and highlights the importance of understanding soil–fungal–plant interactions as key steps in the development of successful strategies to minimize mycotoxin exposure. Highlights Mycotoxins are produced by soil‐borne fungi during pre‐ and post‐harvest stages. Mycotoxins reach human diet directly by contamination of foods or indirectly through animal feeds. Chronic and acute exposure to mycotoxins is a major health hazard. Economic impact from mycotoxin contamination exceeds US$1 billion.